Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 7/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.40 |
| ▸ | ITGAM | P11215 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7380400 | 0.88 | RAB9A (0.48) | RAB9ANPC1SMN1; SMN2CASP1MAPT | |
| SCHEMBL7670357 | 0.87 | RAB9A (0.46) | RAB9ANPC1SMN1; SMN2CASP1MAPT | |
| SCHEMBL7528476 | 0.87 | MAPT (0.44) | RAB9ANPC1SMN1; SMN2CASP1MAPT | |
| SCHEMBL7666223 | 0.84 | ITGB3 (0.46) | ITGB3ITGA2BITGB2ITGAM | |
| SCHEMBL7379113 | 0.82 | RAB9A (0.49) | RAB9ANPC1SMN1; SMN2CASP1MAPT | |
| SCHEMBL7667816 | 0.82 | RAB9A (0.47) | RAB9ANPC1SMN1; SMN2CASP1MAPT | |
| SCHEMBL7668343 | 0.81 | RAB9A (0.46) | RAB9ANPC1SMN1; SMN2CASP1MAPT | |
| SCHEMBL8407625 | 0.80 | ITGB3 (0.48) | SMN1; SMN2ITGB3ITGA2BLMNA | |
| SCHEMBL7672190 | 0.79 | ITGB3 (0.47) | ITGB3ITGA2BITGB2ITGAM | |
| SCHEMBL7373145 | 0.79 | RAB9A (0.51) | RAB9ANPC1SMN1; SMN2CASP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6455560-B1 | SUBSTITUTED (1-((3-ISOXAZOLIN-5-YL)CARBONYL/METHYL) -4-PIPERIDINYL) ACETIC ACID FOR USE IN INHIBITING THE BINDING OF FIBRINOGEN TO BLOOD PLATELETS AND FOR INHIBITING THE AGGREGATION OF BLOOD PLATELETS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-24 | — | — | US | disclosed |
| US-20020082253-A1 | Novel isoxazoline fibrinogen receptor antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-06-27 | — | — | US | disclosed |
| US-6319937-B1 | INHIBITION OF PLATELET AGGREGATION, AS THROMBOLYTICS, AND/OR TREATMENT OF THROMBOEMBOLIC DISORDERS. | DUPONT PHARMACEUTICALS COMPANY | 2001-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082253-A1 | Novel isoxazoline fibrinogen receptor antagonists | FGB, F2, F13B | RAB9A 4095/4885NPC1 3895/4885SMN1; SMN2 4699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.